Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease

Authors

Institutions

Publication Details

Journal
Alzheimer s Research & Therapy
Published
2024-10-23
DOI
https://doi.org/10.1186/s13195-024-01599-1
Citations
74
Primary Topic
Inflammation biomarkers and pathways
Type
article
Field-Weighted Citation Impact
17.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease

Ilaria Tassi, Tuan D. Nguyen, Balasubrahmanyam Budda, Michael E. Ward et al.
74 citations
Alzheimer s Research & Therapy
Inflammation biomarkers and pathways
17.80
article

Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease

Ilaria Tassi, Tuan D. Nguyen, Balasubrahmanyam Budda, Michael E. Ward, Anna Rychkova, Hervé Rhinn, Tina Schwabe, Brady Burgess, Felix L. Yeh, Adam Simmons, Robert Paul, Arthur J. Mayorga, Hua Long, Arnon Rosenthal, Sara Kenkare-Mitra
article en
74 citations

Abstract

No abstract available for this paper.
Alzheimer s Research & TherapyVol. 16(1)
Massachusetts Academy of Math and Science at WPI (US), Rapt Therapeutics (United States) (US), Film Independent (US), Alector (United States) (US), Apple (United States) (US)
Good health and well-being
Openalex Percentile: Top 0%
Inflammation biomarkers and pathways
17.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.